Test: Infection, Tumor imaging, and Therapy study quiz (3/4) (employee training


Infection, Tumor imaging, and Therapy study quiz (3/4)Versión en línea 22-30 slides por Joshua Liberty 1 Lu-177 Dotatate causes myelosuppression. a True b False 2 What is the MOL of Lu-177 Dotatate? a Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells b Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. c Unknown, thought to be increased blood flow and metabolic rate in abnormal cells d Migration via chemotaxis, it is lipophilic and enters leukocyte cell membrane. 3 The beta emission from Lu-177 induces cellular damage by formation of _____ in somatostatin receptor-positive cells and in neighboring cells. a Antioxidants b Citrate buffer c Free radicals d Cold rituximab 4 Within ____ of administration, distributes in kidneys, tumor lesions, liver, spleen, and in some patients, pituitary gland and thyroid. a 1 b 2 c 3 d 4 5 Within four hours of administration, distributes in kidneys, tumor lesions, liver, spleen, and in some patients, pituitary gland and thyroid. a Kidneys b Tumor lesions c Liver d Spleen e Pituitary gland and thyroid f Kidneys, tumor lesions, Liver, spleen, pituitary gland, and thyroid 6 How much does the co-administration of amino acids reduce the median radiation dose to the kidneys by? a 25% b 47% c 50% d 67% e 33% 7 Yttrium-Ibritumomab tiuxetan is used to treat HL a True b False 8 What is the MOL of Y-90-Ibritumomab tiuxetan? a Targets the CD20 antigen on surface of normal/malignant B lymphocytes b Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells c Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. d Unknown, thought to be increased blood flow and metabolic rate in abnormal cells 9 Tp of Y-90 a 64 hours b 78 hours c 73 hours d 66 hours 10 Y-90 decays by? a B-decay b EC c Annihilation reaction d B+ decay 11 Y-90 has different doses depending on lab levels. a True b False 12 If platelet counts are between _____ and ______ the dose should be? a 150,000; 0.3 mCi b 100,000-149000; 0.4 mCi c 100,000-149000; 0.3 mCi d 150,000; 0.4 mCi 13 If platelet counts are less than _________ the dose should be? a >150,000; 0.4 mCi b 100,000-149000; 0.4 mCi c 100,000-149000; 0.3 mCi d <150,000; 0.3 mCi 14 Max dose should not exceed _____ for Y-90 therapy. a 32 uCi b 20-30 mCi c 5-10 mCi d 0.032 Curie 15 Day 1 of Y-90 therapy; ??? a Give IV rituximab (do not bolus), which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills b Prep patient by drawing injection markers on the skill just about center on each tumor site. c Give 2nd infusion IV cold rituimab; within 4 hours: the give therapeutic dose d Patient must discontinue taking Thyroid replacement hormones as it can cause artifacts within the scan 16 Day 7, 8, 9 of Y-90 therapy; ??? a Give 2nd infusion IV cold rituimab; within 4 hours: the give therapeutic dose b Give IV rituximab (do not bolus), which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills c Prep patient by drawing injection markers on the skill just about center on each tumor site. d Patient must discontinue taking Thyroid replacement hormones as it can cause artifacts within the scan 17 What is the Therapeutic dose of Y-90. a 0.3 or 0.4 uCi/kg (<34) mCi b 0.2 or 0.3 mCi/kg (<32) mCi c 0.3 or 0.4 uCi/kg (<32) uCi d 0.3 or 0.4 mCi/kg (<32) mCi 18 Y-90 is a ____ emitter. a Alpha b Gamma c Beta d Photometric effect. 19 What is the most common energy range for Y-90? a 750-935 KeV b 300-600 KeV c 566-827 KeV d 105-318 KeV 20 Which one of the side effects of Y-90 therapy is not a serious side effect? a Cytopenia b Thrombocytopenia c Asthenia d Secondary malignancies e Anemia f Lymphopenia 21 Which one of the side effects of Y-90 therapy is not a minor side effect? a Fatigue b Anemia c Nausea d Abdominal pain e Cough f Pyrexia 22 Thera-spheres are made of resin. a True b False 23 Thera-spheres are made of glass microspheres. a True b False 24 Sir-spheres are made of resin. a True b False 25 Sir-spheres are made of glass microspheres. a True b False 26 How much of all cancers ultimately spread to the liver. a 1/2 b 1/4 c 1/3 d 3/4 27 Thera-spheres are used for the treatment of? a Lung nodules b Primary liver tumor c Adrenal adenoma d Unresectable liver Mets from colorectal cancer 28 Sir-spheres are used for the treatment of? a Lung nodules b Primary liver tumor c Adrenal adenoma d Unresectable liver Mets from colorectal cancer 29 What is the dose for Thera-spheres? a 80-150 mCi b 80-150 uCi c 80-150 Gys d 80-150 Rads 30 What is the dose for Sir-spheres a >50% liver involvement, 3 GBq b 25-50% liver involvement, 2.5 GBq c <25% liver involvement, 2 GBq d <50% liver involvement, 3 GBq e None of these f >50% liver involvement, 3 GBq, 25-50% liver involvement, 2.5 GBq,<25% liver involvement, 2 GBq 31 Prior to the administration of Y-90 labeled Glass microspheres, the patient should undergo? a Hepatic arterial catherization b V/Q scan c GE study d Bone scan 32 Y-90 labeled Glass microspheres is contradicted in patients with? a Tc99m MAA deposition to the GI tract b Shunting of blood to the lungs that could lead to greater than 16.5 mCi of yttrium-90 to the lungs. c COPD d Heart failure e Tc99m MAA deposition to the GI tract, Shunting of blood to the lungs that could lead to greater than 16.5 mCi of yttrium-90 to the lungs. 33 When doing the pre-Y-90 what is the dose? a 2-4 mCi Tc99m DTPA b 5-10 mCi Tc99m Mebrofenin c 5-10 mCi Tc99m MAA d 2-4 mCi Tc99m MAA 34 Y-90 Glass microspheres uses MAA to determine the extent of A-V shunting to the lungs and to confirm the absence of? a Duodenal flow b Gastric flow c Pooling in the cardiac ventricles d In the ureters of the kidneys e Duodenal flow and Gastric flow 35 When is radiation pneumonitis seen in patients? a Pts receiving dose greater than 30 Gy in a single treatment b Pts receiving dose greater than 60 Gy in a single treatment c Pts receiving dose greater than 20 Gy in a single treatment d Pts receiving dose greater than 30 mCi in a single treatment e Pts who already have pneumonia before receiving treatment 36 Microspheres are trapped into liver tumors by embolizing small arterial vessels; use hepatic artery for infusion. a True b False 37 We cannot take pictures using Y-90 spheres. a True b False 38 When are Sir-spheres contradicted? a All of these b Had previous external beam radiation therapy to the liver. c Ascites or are in clinical liver failure d Markedly abnormal synthetic and excretory liver function tests e 20% lung shunting of the hepatic artery blood flow, or >30Gy RAD to the lungs, as estimated by MAA scan 39 I-125 half-life is? a 64 days b 59.6 days c 13.2 hours d 8 days 40 Which of the following statements about I-125 is true? a Decays by EC, 27.4 and 31 keV x-rays and a 35.5 keV gamma. b Decays by EC, 27.4 and 31 keV gamma rays and a 35.5 keV x-ray. c Decays by B-, 27.4 and 31 keV x-rays and a 35.5 keV gamma. d Decays by EC, 27.4 keV x-ray and a 35.5 keV gamma. 41 I-125 implant seeds are used for? a Permanent interstitial treatment of selected localized tumors. b Castrate resistant Prostate cancer c Primary liver tumor d Unresectable liver mets from colorectal cancer 42 Implants may be used in ? a Head b Neck c Lung d Pancreas e Early stage prostate f All of these 43 Implants are administered? a Superficial b Intra-abdominal c Intra thoracic d All these locations e None of these locations 44 Seeds do not have to be sterile. a True b False 45 Seeds are strictly controlled and are stored in a cabinet in the hot lab. a True b False Feedback 7 NHL 37 Bremsstrahlung radiation can be used to form a crude picture of Y-90 liver distribution by SPECT. 44 They start non sterile but for administration they have to be sterilized. 45 False they are stored in a hot lab but in a locked safe.

1

Lu-177 Dotatate causes myelosuppression.

a

True

b

False

2

What is the MOL of Lu-177 Dotatate?

a

Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells

b

Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized.

c

Unknown, thought to be increased blood flow and metabolic rate in abnormal cells

d

Migration via chemotaxis, it is lipophilic and enters leukocyte cell membrane.

3

The beta emission from Lu-177 induces cellular damage by formation of _____ in somatostatin receptor-positive cells and in neighboring cells.

a

Antioxidants

b

Citrate buffer

c

Free radicals

d

Cold rituximab

4

Within ____ of administration, distributes in kidneys, tumor lesions, liver, spleen, and in some patients, pituitary gland and thyroid.

a

1

b

2

c

3

d

4

5

Within four hours of administration, distributes in kidneys, tumor lesions, liver, spleen, and in some patients, pituitary gland and thyroid.

a

Kidneys

b

Tumor lesions

c

Liver

d

Spleen

e

Pituitary gland and thyroid

f

Kidneys, tumor lesions, Liver, spleen, pituitary gland, and thyroid

6

How much does the co-administration of amino acids reduce the median radiation dose to the kidneys by?

a

25%

b

47%

c

50%

d

67%

e

33%

7

Yttrium-Ibritumomab tiuxetan is used to treat HL

a

True

b

False

8

What is the MOL of Y-90-Ibritumomab tiuxetan?

a

Targets the CD20 antigen on surface of normal/malignant B lymphocytes

b

Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells

c

Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized.

d

Unknown, thought to be increased blood flow and metabolic rate in abnormal cells

9

Tp of Y-90

a

64 hours

b

78 hours

c

73 hours

d

66 hours

10

Y-90 decays by?

a

B-decay

b

EC

c

Annihilation reaction

d

B+ decay

11

Y-90 has different doses depending on lab levels.

a

True

b

False

12

If platelet counts are between _ and __ the dose should be?

a

150,000; 0.3 mCi

b

100,000-149000; 0.4 mCi

c

100,000-149000; 0.3 mCi

d

150,000; 0.4 mCi

13

If platelet counts are less than _________ the dose should be?

a

>150,000; 0.4 mCi

b

100,000-149000; 0.4 mCi

c

100,000-149000; 0.3 mCi

d

<150,000; 0.3 mCi

14

Max dose should not exceed _____ for Y-90 therapy.

a

32 uCi

b

20-30 mCi

c

5-10 mCi

d

0.032 Curie

15

Day 1 of Y-90 therapy; ???

a

Give IV rituximab (do not bolus), which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills

b

Prep patient by drawing injection markers on the skill just about center on each tumor site.

c

Give 2nd infusion IV cold rituimab; within 4 hours: the give therapeutic dose

d

Patient must discontinue taking Thyroid replacement hormones as it can cause artifacts within the scan

16

Day 7, 8, 9 of Y-90 therapy; ???

a

Give 2nd infusion IV cold rituimab; within 4 hours: the give therapeutic dose

b

Give IV rituximab (do not bolus), which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills

c

Prep patient by drawing injection markers on the skill just about center on each tumor site.

d

Patient must discontinue taking Thyroid replacement hormones as it can cause artifacts within the scan

17

What is the Therapeutic dose of Y-90.

a

0.3 or 0.4 uCi/kg (<34) mCi

b

0.2 or 0.3 mCi/kg (<32) mCi

c

0.3 or 0.4 uCi/kg (<32) uCi

d

0.3 or 0.4 mCi/kg (<32) mCi

18

Y-90 is a ____ emitter.

a

Alpha

b

Gamma

c

Beta

d

Photometric effect.

19

What is the most common energy range for Y-90?

a

750-935 KeV

b

300-600 KeV

c

566-827 KeV

d

105-318 KeV

20

Which one of the side effects of Y-90 therapy is not a serious side effect?

a

Cytopenia

b

Thrombocytopenia

c

Asthenia

d

Secondary malignancies

e

Anemia

f

Lymphopenia

21

Which one of the side effects of Y-90 therapy is not a minor side effect?

a

Fatigue

b

Anemia

c

Nausea

d

Abdominal pain

e

Cough

f

Pyrexia

22

Thera-spheres are made of resin.

a

True

b

False

23

Thera-spheres are made of glass microspheres.

a

True

b

False

24

Sir-spheres are made of resin.

a

True

b

False

25

Sir-spheres are made of glass microspheres.

a

True

b

False

26

How much of all cancers ultimately spread to the liver.

a

1/2

b

1/4

c

1/3

d

3/4

27

Thera-spheres are used for the treatment of?

a

Lung nodules

b

Primary liver tumor

c

Adrenal adenoma

d

Unresectable liver Mets from colorectal cancer

28

Sir-spheres are used for the treatment of?

a

Lung nodules

b

Primary liver tumor

c

Adrenal adenoma

d

Unresectable liver Mets from colorectal cancer

29

What is the dose for Thera-spheres?

a

80-150 mCi

b

80-150 uCi

c

80-150 Gys

d

80-150 Rads

30

What is the dose for Sir-spheres

a

>50% liver involvement, 3 GBq

b

25-50% liver involvement, 2.5 GBq

c

<25% liver involvement, 2 GBq

d

<50% liver involvement, 3 GBq

e

None of these

f

>50% liver involvement, 3 GBq, 25-50% liver involvement, 2.5 GBq,<25% liver involvement, 2 GBq

31

Prior to the administration of Y-90 labeled Glass microspheres, the patient should undergo?

a

Hepatic arterial catherization

b

V/Q scan

c

GE study

d

Bone scan

32

Y-90 labeled Glass microspheres is contradicted in patients with?

a

Tc99m MAA deposition to the GI tract

b

Shunting of blood to the lungs that could lead to greater than 16.5 mCi of yttrium-90 to the lungs.

c

COPD

d

Heart failure

e

Tc99m MAA deposition to the GI tract, Shunting of blood to the lungs that could lead to greater than 16.5 mCi of yttrium-90 to the lungs.

33

When doing the pre-Y-90 what is the dose?

a

2-4 mCi Tc99m DTPA

b

5-10 mCi Tc99m Mebrofenin

c

5-10 mCi Tc99m MAA

d

2-4 mCi Tc99m MAA

34

Y-90 Glass microspheres uses MAA to determine the extent of A-V shunting to the lungs and to confirm the absence of?

a

Duodenal flow

b

Gastric flow

c

Pooling in the cardiac ventricles

d

In the ureters of the kidneys

e

Duodenal flow and Gastric flow

35

When is radiation pneumonitis seen in patients?

a

Pts receiving dose greater than 30 Gy in a single treatment

b

Pts receiving dose greater than 60 Gy in a single treatment

c

Pts receiving dose greater than 20 Gy in a single treatment

d

Pts receiving dose greater than 30 mCi in a single treatment

e

Pts who already have pneumonia before receiving treatment

36

Microspheres are trapped into liver tumors by embolizing small arterial vessels; use hepatic artery for infusion.

a

True

b

False

37

We cannot take pictures using Y-90 spheres.

a

True

b

False

38

When are Sir-spheres contradicted?

a

All of these

b

Had previous external beam radiation therapy to the liver.

c

Ascites or are in clinical liver failure

d

Markedly abnormal synthetic and excretory liver function tests

e

20% lung shunting of the hepatic artery blood flow, or >30Gy RAD to the lungs, as estimated by MAA scan

39

I-125 half-life is?

a

64 days

b

59.6 days

c

13.2 hours

d

8 days

40

Which of the following statements about I-125 is true?

a

Decays by EC, 27.4 and 31 keV x-rays and a 35.5 keV gamma.

b

Decays by EC, 27.4 and 31 keV gamma rays and a 35.5 keV x-ray.

c

Decays by B-, 27.4 and 31 keV x-rays and a 35.5 keV gamma.

d

Decays by EC, 27.4 keV x-ray and a 35.5 keV gamma.

41

I-125 implant seeds are used for?

a

Permanent interstitial treatment of selected localized tumors.

b

Castrate resistant Prostate cancer

c

Primary liver tumor

d

Unresectable liver mets from colorectal cancer

42

Implants may be used in ?

a

Head

b

Neck

c

Lung

d

Pancreas

e

Early stage prostate

f

All of these

43

Implants are administered?

a

Superficial

b

Intra-abdominal

c

Intra thoracic

d

All these locations

e

None of these locations

44

Seeds do not have to be sterile.

a

True

b

False

45

Seeds are strictly controlled and are stored in a cabinet in the hot lab.

a

True

b

False

Feedback

7

NHL

37

Bremsstrahlung radiation can be used to form a crude picture of Y-90 liver distribution by SPECT.

44

They start non sterile but for administration they have to be sterilized.

45

False they are stored in a hot lab but in a locked safe.

Infection, Tumor imaging, and Therapy study quiz (3/4)

Test

Descarga la versión para jugar en papel

Creada por

Top 10 resultados

Top juegos

Test

Tipos de sintagmas (II)

Test

Verbos irregulares en Inglés

Test

Brawl stars preguntas

Test

Cultura general española

Test

cuanto sabes de Futbol